GW Pharmaceuticals PLC- (GWPH) Getting Somewhat Positive Media Coverage, Analysis Shows
Media headlines about GW Pharmaceuticals PLC- (NASDAQ:GWPH) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GW Pharmaceuticals PLC- earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.4690091366438 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:
- GW Pharmaceuticals PLC- (GWPH) Given Average Rating of “Hold” by Brokerages (americanbankingnews.com)
- GW Pharmaceuticals plc (GWPH) Stock price bearish move to its 20 SMA, receiving attraction form Day Traders – Analyst Recommendation (press release) (blog) (analystrecommendation.com)
- GW Pharmaceuticals plc (GWPH) stock is now worth at $116.53 while Analyst mean rating stands at 2.10 – Nasdaq Fortune (press release) (nasdaqfortune.com)
- GW Pharmaceuticals plc (GWPH) crosses 50- SMA down along -10.20% – The Stocks News (press release) (thestocksnews.com)
- GW Pharmaceuticals plc (GWPH) Stock Price trades 1.96% off from 200- SMA – Nasdaq Chronicle (nasdaqchronicle.com)
Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) opened at $117.04 on Friday. The stock has a market cap of $3,210.00, a PE ratio of -13.22 and a beta of 2.63. The company has a quick ratio of 11.34, a current ratio of 11.44 and a debt-to-equity ratio of 0.01. GW Pharmaceuticals PLC- has a twelve month low of $92.65 and a twelve month high of $143.37.
A number of equities analysts have commented on GWPH shares. BidaskClub raised shares of GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a research note on Friday, December 22nd. Goldman Sachs Group raised shares of GW Pharmaceuticals PLC- from a “neutral” rating to a “buy” rating and set a $174.00 price objective for the company in a research note on Thursday, December 14th. Cantor Fitzgerald set a $208.00 price objective on shares of GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a research note on Monday, December 4th. Bank of America dropped their price objective on shares of GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a “buy” rating for the company in a research note on Tuesday, November 14th. Finally, Leerink Swann reissued a “buy” rating and issued a $153.00 price objective on shares of GW Pharmaceuticals PLC- in a research note on Tuesday, January 23rd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. GW Pharmaceuticals PLC- has a consensus rating of “Hold” and a consensus price target of $146.38.
COPYRIGHT VIOLATION NOTICE: “GW Pharmaceuticals PLC- (GWPH) Getting Somewhat Positive Media Coverage, Analysis Shows” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2018/03/11/gw-pharmaceuticals-plc-gwph-getting-somewhat-positive-media-coverage-analysis-shows.html.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.